Elizabeth Holmes Documentary Breaks Box Office Records, Theranos Claims High Valuation Through Blood Testing Technology, Later Proven Unfulfilled
The documentary "You Can See Everything," co-directed by Nathan Fielder and Lance Oppenheim, premiered in limited theaters in North America on October 16. The film documents Elizabeth Holmes' life 34 days before her imprisonment in 2023.
The opening weekend box office was approximately $15 million from 855 screens, marking the highest opening for a non-concert documentary since "Fahrenheit 9/11" in 2004. It ranked second overall for the weekend, only behind "Street Fighter," with over 2,000 sold-out screenings.
Holmes is the founder of Theranos, which was convicted of defrauding investors in 2022 and sentenced to 11 years and 3 months in prison. She began serving her sentence in a Texas minimum-security prison in May 2023. The film was distributed by A24, with a production cost of about $7 million.
The film received widespread acclaim after its secret premiere at the Telluride Film Festival. It has a Rotten Tomatoes score of about 97% and a Metacritic score of approximately 97. Over 70% of the audience is under 35 years old.
Theranos claimed a high valuation through its blood testing technology, which was later proven unfulfilled. Related investigative reports prompted the case to become public. Holmes appears in the film with her partner Billy Evans and their children.
In terms of market mechanisms, the high average box office in limited theaters indicates demand driven by content. Beneficiaries include A24 and the production team, while traditional documentary distribution models face pressure.
Source: Public Information
ABAB AI Insight
Elizabeth Holmes founded Theranos, which once received high valuations and media attention. The company's technology claims were unfulfilled, leading to investigations and lawsuits. John Carreyrou's reporting propelled the case forward.
In terms of capital pathways, early financing and media exposure supported the valuation. After failure, the focus shifted to legal proceedings and content production. The documentary achieved theatrical release and box office returns, continuing the consumption of related content.
This is similar to other high-valuation tech companies that enter judicial and media reproduction after failing to fulfill technological promises. It is currently in a phase of secondary consumption of content following the conclusion of the original case.
Essentially, this represents a transfer of pricing power. The focus shifts from technological promises and capital valuations to judicial outcomes and narrative content pricing; audiences pay to view the private records of a convicted individual.
ABAB News · Cognitive Laws
High valuation promises lead to content reproduction after failure
High box office in limited theaters indicates narrative scarcity
Conclusion of the original case does not terminate related consumption